AstraZeneca Ua Tau Zoo Tom ntej-Tiam Qhov Ncauj PCSK9 Tus Inhibitor

Tsis ntev los no, AstraZeneca tau kos npe rau kev pom zoo nrog Dogma Therapeutics kom tau txais nws qhov ncauj PCSK9 inhibitor qhov kev pab cuam, thiab npaj yuav nce nws mus rau tib neeg kev soj ntsuam sim lwm xyoo los soj ntsuam cov teebmeem ntawm qhov ncauj PCSK9 inhibitors hauv tib neeg.

PCSK9 inhibitors pom tias yog qhov kev loj hlob loj tshaj plaws hauv lipid-txo qis tom qab statins, tab sis lawv cov peev xwm muag hnyav tseem tsis tau pom tseeb hauv kev ua lag luam. Tam sim no, muaj ob lub PCSK9 tshuaj tiv thaiv ntawm kev muag, uas yog Amgen's Repatha thiab Sanofi / Regeneron tus Praluent. Ob tog tau sib koom ua rog nqe nqe hnyav.

Txawm hais tias muaj ntau qhov kev sim tshuaj ntsuam pom tau pom tias kev siv cov tshuaj no tuaj yeem txo qis kev mob plawv los ntawm 15-20%, kev siv cov tshuaj tiv thaiv PCSK9 inhibitors sib kis tau dav dav vim tias lawv tus nqi-ua haujlwm tau zoo.

Lwm txoj hauv kev los tiv thaiv PCSK9 kuj tseem cuam tshuam los ntawm qhov dav ntawm qhov chaw khi uas tiv thaiv los ntawm cov tshuaj tiv thaiv, thiab txog tam sim no, tsuas yog cov hau kev rau kev cuam tshuam ncaj qha ntawm PCSK9 siv me me molecules tau tshaj tawm.

Tsaib no, nrog kev pab los ntawm Charles River Lub chaw soj nstuam, ib lub chaw tsim tshuaj tawm kev txhim kho tshuaj, Dogma Kev Kho Mob sawv. Lub tuam txhab siv nws lub platform nrhiav cov txheej txheem me me molecule inhibitor uas tuaj yeem khi ncaj qha rau cov hnab tshos tshiab thiab cov nqi sib txawv hauv PCSK9.

Raws li lub tuam txhab, hauv kev sim ua ntej, cov tib neeg tsis muaj kabmob nrog dyslipidemia tau kho los ntawm kev tswj hwm qhov ncauj, thiab nws tau pom tias nws lub qhov ncauj PCSK9 me me molecule inhibitor" Tom qab ob peb lub lis piam ntawm kev tswj hwm, LDL-C pom tias tseem ceeb thiab txo qis."

Tam sim no, AstraZeneca vam tias yuav tau txais cov txheej txheem tom ntej no. Cov ntsiab lus hais txog nyiaj txiag ntawm daim ntawv cog lus tso cai koom tes no tsis muab qhia tawm. Raws li cov lus tshaj tawm, AstraZeneca yuav npaj ua ntej peb tes num mus rau hauv kev kho mob ntawm dyslipidemia thiab tsev neeg hypercholesterolemia.

Txawm hais tias PCSK9 yog qhov tseeb uas yuav txo tau LDL-C kom zoo, nws tau ua rau nws nyuaj rau nws nrog cov lwg me me. Qhov kev tso cai pom zoo no nrog Dogma Kev Kho Mob yuav muab AstraZeneca nrog txoj hauv kev los tsim thawj cov tshuaj me me, qhov ncauj muaj PCSK9 inhibitor.

Ntxiv nrog rau cov tshuaj monoclonal antibody, kuj tseem muaj kev kho mob tshiab txog yuav tsum tau nyob rau hauv kev ua lag luam, uas yog Novartis' inclisiran, uas tau nrhiav los ntawm kev muab TMC rau $ 9.4 nphom. Cov tshuaj yog ib hom siRNA uas siv RNA cuam tshuam los cuam tshuam rau kev sib txuas lus ncaj qha ntawm PCSK9 protein hauv lub siab, thiab tau qhia tias muaj kev cuam tshuam zoo hauv kev sim kho mob.

Tam sim no, inclisiran tab tom kuaj xyuas ntxawg hauv Tebchaws Meskas thiab Europe. Nrog txoj kev tau zoo ntawm kev txhaj tshuaj subcutaneous ib xyoos ob zaug, inclisiran ua txhua yam rau muaj kev cuam tshuam kev ua phem rau ob lub cev tiv thaiv kab mob PCSK9 inhibitors.